Australian TGA rules on prescription-medicine advertising — and why our site reads this way

If you've poked around the Fusenite site and noticed we never name a specific medication on the public pages, here's why — and what we can talk about during your consultation.

The legal rule

Australia's Therapeutic Goods Act (sections 42DL and 42DLB) prohibits any advertising of Schedule 4 prescription medicines to the general public. The penalty for breach is up to AU$1.65M per offence for an individual and AU$16.5M for a corporation. The TGA has been actively enforcing this — recent fines in our sector include $198,000 against one operator and a $319,260 sweep across four others.

What counts as advertising

Anything on a public-facing page that names or promotes a Schedule 4 medicine. This includes product names, generic names, drug-class shorthand, before/after photos that imply the use of a particular medication, and even patient testimonials that name a treatment. The TGA has fined operators for indirect references too — phrases like "plant medicine" used to describe Schedule 4 substances have triggered enforcement.

What we can do during a consultation

Once you're in a real-time consultation with an AHPRA-registered Fusenite doctor, the conversation is between you and your clinician. The same restrictions don't apply — your doctor will discuss specific options, mechanisms, side effects, alternatives, and what they recommend for your particular situation.

Why this is actually OK

The rule exists for a reason. Direct-to-consumer drug advertising tends to drive demand for medications irrespective of clinical need. Australia's approach — clinical decisions in the consult room, not in the marketing funnel — produces better outcomes. We agree with it, even where it makes our marketing harder.

This is general health information and not medical advice. Your doctor will discuss your specific situation during a consultation.